Ardelyx (ARDX) Gains from Investment Securities (2014)

Ardelyx (ARDX) posted Gains from Investment Securities of -$1.0 million for Q2 2014, down 138.8% on a QoQ basis from $2.6 million in Q1 2014.

Ardelyx (ARDX) Gains from Investment Securities (2014) Analysis & Trends

Ardelyx's Gains from Investment Securities history runs 1 years deep, the most recent figure standing at -$1.0 million for Q2 2014.

Quarterly Gains from Investment Securities changed N/A year-over-year to -$1.0 million in Q2 2014, while the trailing twelve-month figure through Sep 2015 was -$1.0 million (changed N/A YoY) and the FY2014 annual result came in at $1.6 million, down 54.56% from the prior year.
Gains from Investment Securities was -$1.0 million for Q2 2014 at Ardelyx, down from $2.6 million in the prior quarter.
Across five years, Gains from Investment Securities topped out at $2.6 million in Q1 2014 and bottomed at -$1.0 million in Q2 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Ardelyx	1.26 Bn	1.02 Bn	89.66 Mn

Download Data